Skip to content
Search

Latest Stories

BMI linked to work absenteeism, NHS expands obesity and type 2 diabetes programme

BMI linked to work absenteeism, NHS expands obesity and type 2 diabetes programme
Wider rollout of NHS soup and shake diet to help 10,000+ with type 2 diabetes and obesity

A recent study presented at the European Congress on Obesity in Venice sheds light on the detrimental effects of obesity on workplace absenteeism and economic productivity.

The analysis, encompassing data from millions of workers across Europe, reveals a direct correlation between body mass index (BMI) and the likelihood of taking sick leave.


According to the study, obese individuals are up to twice as likely to take time off work due to health issues compared to those of a healthy weight.

The increased sick notes among obese individuals is attributed to various complications associated with obesity, including joint pain, diabetes, depression, and heart disease.

In the United Kingdom, where obesity rates are among the highest in Europe, the impact of obesity on workplace absenteeism is particularly pronounced.

The study indicates that soaring obesity levels contribute significantly to the country's record sickness levels, with approximately 2.8 million people currently signed off work due to health issues.

It underscores the urgency of implementing anti-obesity measures to promote economic growth and reduce the economic impact of obesity-related health conditions.

Furthermore, the rising sick note culture in the UK, characterised by a doubling in the number of sick notes issued by the NHS over the past decade, poses a significant economic burden, as per the The Sunday Times. 

The estimated cost of rising sick leave is a staggering £33 billion annually in lost productivity.

In response to these findings, prime minister Rishi Sunak has announced reforms aimed at addressing the "sick-note culture," emphasising the need to tackle obesity as a root cause of health problems driving individuals out of the workforce.

NHS 'Soup and Shake Diets' to tackle obesity epidemic in 42 local health areas 

The NHS's rollout of "soup and shake" diets as part of efforts to tackle obesity and reverse type 2 diabetes represents a significant step towards addressing the obesity epidemic.

Under the new expansion plan, the NHS Type 2 Diabetes Path to Remission Programme will double its capacity, benefiting over 10,000 individuals struggling with type 2 diabetes and excess weight or obesity.

This national rollout will cover 42 local health areas, ensuring accessibility for eligible patients across the country.

Patients referred by the GPs will be given diet replacement products like milkshakes and soups with 800 to 900 calories per day upto 3 months along with support from diet coaches and clinicians to tackle obesity and related conditions.

According to The Telegraph, more than 50,000 people are set to sign up for the obesity programme in the coming 5 years costing an average of £1,000 per head for the weight loss plan.

Health chiefs are investing £13 million this year to support the programme’s expansion, and since the peak of the Covid-19 pandemic, local NHS teams have been given £36 million by NHS England to help restore their diabetes services to pre-pandemic levels.

Amanda Pritchard, NHS chief executive, emphasised the life-changing potential of the programme, stating that the new rollout "can be truly life-changing in helping reverse the effects of the condition."

Emphasising on holistic approach to tackling obesity and type 2 diabetes, the NHS National Clinical Director for Diabetes and Obesity, Dr Clare Hambling said:

“Our NHS Type 2 Diabetes Path to Remission Programme, sits alongside the success of our world-leading Healthier You NHS Diabetes Prevention Programme – which independent evaluation has shown to successfully reduce the risk of developing type 2 diabetes by more than a third for people who complete the programme.”

More For You

ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
Majority of Brits neglect consistent skincare routine,  survey finds

On average, Brits go to bed without washing their face twice a week.

Photo credit: gettyimages

Skincare: One in five Brits go to bed without washing their face daily, survey finds

Nearly two-thirds of Brits (60 per cent) neglect a consistent skincare routine,with almost one in five going to bed without washing their face daily, according to a new survey by consumer health company Kenvue.

The UK-wide survey of 2,000 people revealed that one-third of respondents (34 per cent) spend five minutes or less on their daily skincare routine. On average, Brits go to bed without washing their face twice a week.

Keep ReadingShow less
Risk of pharmacy closures remains despite record funding uplift

Community pharmacy sector remains in a fragile position as the funding gap is still significant, says CCA.

gettyimages

Pharmacy closures still a risk as funding deal fails to cover costs – warns CCA

The community pharmacy sector has secured the largest funding uplift across the NHS, yet concerns remain that it may not be enough to prevent further closures and service reductions.

Following a six-week consultation with Community Pharmacy England (CPE), the government has approved a £3.073 billion funding package for 2025/26, supplemented by an additional £215 million to support Pharmacy First and other Primary Care Recovery Plan services.

Keep ReadingShow less
​The next generation of BD Rowa Smart launched

The latest BD Rowa™ Smart introduces a more intuitive user interface.

Photo credit: BD Rowa

BD Rowa unveils next-generation smart dispensing robot with sustainable design

Leading medical technology company BD Rowa has announced the launch of the next generation of its smart dispensing robot, offering enhanced convenience with a sustainable design.

Currently in its final development phase, the latest BD Rowa™ Smart introduces a more intuitive user interface designed to streamline operations and enhance the user experience.

Keep ReadingShow less
Independent Prescribing: Government aims to complete pathfinder programme evaluation by autumn 2025

Pharmacist prescribers at 210 ‘pathfinder’ sites were allowed to trial prescribing models within integrated primary care services.

Photo credit: gettyimages

Independent prescribing: Pathfinder programme evaluation to be completed by autumn, says Kinnock

Health minister Stephen Kinnock has revealed that the evaluation of the Community Pharmacy Independent Prescribing Pathfinder Programme could be completed by Autumn 2025.

Kinnock was responding to a question from James Naish, Labour MP for Rushcliffe, who asked what steps the minister was taking to ensure continued support for the Pathfinder Programme and independent prescribing to maximise direct prescribing capacity in England.

Keep ReadingShow less